2013 NLA Scientific Sessions Highlights
Promise and Pitfalls of Lifetime Risk Assessment for CVDFaculty: Donald Lloyd-Jones, MD
Donald Lloyd-Jones, MD presented there is no Lifetime Risk versus Ten Year Risk but rather Lifetime Risk is an addition to Ten Year Risk. Dr. Lloyd-Jones concludes that Lifetime Risk helps with "high-risk strategy" it can help identify younger individuals with low short-term risk but with a high lifetime risk.
NLA HDL Consensus StatementFaculty: Peter P. Toth, MD, PhD, FNLA
Peter P. Toth, MD, PhD, presented the National Lipid Association's HDL Consensus Statement that is set to be published in the Journal of Clinical Lipidology in the November/December issue.
DHA AND THE BRAIN: Is it an Essential Nutrient?Faculty: Susan E. Carlson, PhD
Susan Carlson, PhD, presented that while DHA is essential for optimal brain function, much more research is needed to be able to determine if it is an essential nutrient for persons consuming α-linolenic acid.
Guidelines for Cardiovascular Health and Risk Reduction in Children and AdolescentsFaculty: Don P. Wilson, MD
Don P. Wilson, MD, presented that over the past three decades it has become evident that atherosclerosis has its origins in childhood. Children and adolescents with genetic and/or acquired CVD risk factors can be easily identified. When present at a young age, these risk factors track into adulthood and have been associated with moderate-to-high risk of future cardiovascular disease.
HPS2-THRIVEFaculty: Jane Armitage, FRCP, FFPH
Jane Armitage, FRCP, FFPH, presented the HPS-2 THRIVE clinical trial. During her talk, Professor Armitage conveys that the trial found no significant benefit of ER niacin/laropiprant on the primary outcome of major vascular events when added to optimal statin-based LDL-lowering therapy. In addition, results from HPS-2 THRIVE showed significant excesses of serious adverse events (SAEs) due to known and unrecognized side-effects of niacin.
Personalize Antiplatelet Therapy: State of the ArtFaculty: Paul Gurbel, MD
Paul Gurbel, MD, presented that dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor blocker is a key strategy in patients with high risk coronary artery disease patients to reduce platelet reactivity and subsequent thrombotic cardiovascular event occurrence. High on-treatment platelet reactivity to adenosine diphosphate (HPR) is a strong risk factor for post-PCI ischemic event occurrence.
Obesity, Adiposity, and Dyslipidemia: A Consensus Statement from the NLAFaculty: Harold Bays, MD
Harold Bays, MD, presented that fat cells (adipocytes) and body fat (adipose tissue) store the greatest amount of body lipids (e.g., triglycerides and cholesterol). Increased body fat often worsens lipid blood levels, which may increase atherosclerotic heart disease risk in overweight patients.
Statin Therapy and Incident DiabetesFaculty: Paul M. Ridker, MD
Paul Ridker, MD presented the history behind the JUPITER trial and their hypothesis which evaluated whether or not statin therapy would reduce the risk of type-II diabetes in a primary prevention population.
Preparing for Guidelines in 2013Faculty: Neil Stone, MD, MACP, FAHA, FACC, FNLA
Neil Stone, MD, Chair for the ATP IV Panel, presented the process of how the panel was asked to use evidence gathered from randomized clinical trials, systematic reviews and meta-analyses that had been rated for quality by an independent contractor.